CD8A and neoplasm: Another radiotracer with specificity for CD8+ T-cells, 89Zr-desferrioxamine–labeled anti-CD8 cys-diabody, demonstrated the ability to detect changes in tumor infiltrating CD8+ T-cell expression in immunocompetent murine syngeneic tumor immunotherapy models receiving anti-PD-L1 antibodies [54].